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Chronic viral infections can appear in two very different forms: those that are typically immunologi-
cally contained after acute symptomatic infection, such as Epstein-Barr virus (EBV), and those that
predictably lead to persistent viremia and progressive clinical disease. Human immunodeficiency vi-
rus (HIV) infection is typical of the latter and has resulted in more than 20 million deaths worldwide.
Here we review a remarkable subset of persons infected with HIV who are able to achieve long-term
control of viremia and avoid immunodeficiency without the need for antiviral therapy. We review the
contributing role of host genetic factors, innate and adaptive immune responses, and viral factors
that may contribute to this phenotype. These individuals indicate that as with other potentially path-
ogenic chronic viral infections, the human immune system is able to fully control HIV and prevent HIV-
associated disease, at least in some individuals. Further understanding of the mechanisms whereby
this occurs should yield critical insights for prophylactic and therapeutic antiviral interventions.Introduction
More than two decades after the discovery of the etiologic
agent of the acquired immune deficiency syndrome
(AIDS), the global epidemic continues to expand, and
more than 60 million persons have been infected world-
wide. Despite marked sequence heterogeneity among hu-
man immunodefiency virus (HIV) strains, which can be up
to almost 40% within the envelope protein, the clinical
course of disease is often quite predictable. An initial
symptomatic illness that mimics infectious mononucleo-
sis with fever, pharyngitis, lymphadenopathy, and malaise
is followed by an asymptomatic period of approximately
8–10 years in untreated persons, during which time there
is ongoing viral replication and progressive HIV-mediated
loss of CD4+ T cells. Most antiretroviral-untreated individ-
uals eventually develop profound immunodeficiency and
die from AIDS-related complications, with time to death
being approximately 10 years after becoming infected.
Ultimate control of the HIV epidemic will require preven-
tion of new infections, and as the global epidemic con-
tinues to expand, there has never been a greater need
for an effective vaccine. Developing an effective AIDS vac-
cine that prevents infection may not be feasible (Letvin,
2007, this issue of Immunity), so current vaccine strategies
are focused on protection from disease progression (Pan-
taleo and Koup, 2004). This strategy could curtail the
global epidemic, even if immunized persons became
infected, as long as the viral load in the vaccinated indivi-
duals remains low enough to prevent subsequent trans-
mission events (Gray et al., 2001).
Remarkably, a state of apparent durable control of HIV
replication does occur in a very small percentage of un-406 Immunity 27, September 2007 ª2007 Elsevier Inc.treated infected persons. These persons are positive by
standard HIV antibody tests yet lack measurable virus in
plasma by standard clinical assays (i.e., plasma viral loads
are consistently below 50–75 RNA copies/mL). As sug-
gested by their now widely accepted name, these ‘‘elite’’
controllers are exceedingly rare, with most estimates indi-
cating that they make up well less than 1% of the infected
population (Hubert et al., 2000). Some have now had
documented untreated infection for more than 25 years,
providing clear evidence that durable containment of
HIV in the absence of therapy is possible. Understanding
the mechanisms of HIV control in these individuals is likely
to provide critical information for current vaccine strate-
gies. Moreover, given the increasing availability of biologic
agents that can modify host responses, defining the
mechanisms of successful control of a chronic human viral
infection in vivo could lead to the development of novel
immune-based therapeutic strategies for those persons
with otherwise progressive infections.
Here we review what is known, what is assumed, and
what is not known about these potentially highly informa-
tive individuals. An additional purpose is to outline an
unprecedented international collaborative effort among
researchers, health care workers, AIDS service organiza-
tions, and HIV-infected persons to recruit large numbers
of HIV controllers to define the genetic basis for this
remarkable ability to durably contain HIV, which will
hopefully guide new therapeutic and vaccine efforts.
Prevalence and Natural History of HIV Controllers
The vast majority of untreated HIV-infected individuals ex-
hibit evidence of ongoing viral replication and progressive
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fected individuals (5%–15%) remain clinically and/or im-
munologically stable for years (Cao et al., 1995; Munoz
et al., 1995; Pantaleo et al., 1995; Sheppard et al., 1993).
The term ‘‘long-term nonprogressor’’ was coined for
such persons and was generally defined based on dura-
tion of infection and CD4+ T cell count, because viral
load testing did not become available until the mid-
1990s. As viral load testing became available, most
long-term nonprogressors were shown to have low to
moderate amounts of viremia, and further follow-up re-
vealed that many had progressively increasing viral loads
and declining CD4+ T cell counts (Goudsmit et al., 2002;
Lefrere et al., 1997; O’Brien et al., 1996; Rodes et al.,
2004). At the same time, it became clear that a subset of
these individuals was able to maintain viral loads below
the limits of detection (<50 copies HIVRNA/mL). These
individuals are now often referred to as ‘‘elite controllers’’
or ‘‘elite suppressors’’ and are referred to in this review
simply as ‘‘HIV controllers’’ (Figure 1).
Given the importance of understanding the viral-host in-
teraction in these persons, we and others have estab-
lished the International HIV Controller Consortium and
are using the following criteria for enrollment: (1) HIV anti-
body positive as defined by serologic determinations, (2)
no antiretroviral therapy in the preceding 12month period,
and (3) at least three plasma HIV RNA determinations that
are taken during this period that span at least 12 months,
all of which must be below the limit of detection by
Figure 1. Distinctions between Elite Controllers and HIV
Long-Term Nonprogressors
HIV (or ‘‘elite’’) controllers are defined as having undetectable viremia
by standard assays (<50 copies RNA/mL) whereas long-term non-
progressors are most often defined by ability to maintain normal
CD4+ T cell counts for prolonged periods (>10 years). The prevalence
of controllers in most cohorts appears to be much lower than the prev-
alence of nonprogressors. Although most controllers exhibit minimal
rates of CD4+ T cell decline over time, some do progress. Similarly, al-
though some long-term nonprogressors have undetectable viremia,
many if not most have viral loads that are low but detectable. Studies
aimed at definingmechanisms of virus control should focus on control-
lers, and studies focused on mechanisms of immunologic progression
should also consider CD4+ T cell count outcomes.currently available clinical assays (50 or 75 RNA copies/
mL). Some such individuals have now been infected for
more than 25 years, with maintenance of CD4+ T cell
counts and persistent viral loads below the limits of detec-
tion. Others have subsequently progressed (Hunt et al.,
2007), and therefore, close follow-up of large cohorts
may allow one to define the parameters associated with
control followed by loss of control.
The prevalence of HIV controllers among the HIV-
infected population remains poorly defined. In a French
cohort of 330 patients with early infection, only 12 subjects
(4%) presented with a viral load <200 RNA/mL, but only
one (0.3%) had a viral load <20 copies (Hubert et al.,
2000). Amongmore than 2000 individuals identified during
early HIV infection in a second cohort, 6.7% had at least
two consecutive viral loads below the limit of detection
by less sensitive assays (<400 or <500 copies RNA/mL)
(Madec et al., 2005a), but the majority of these recently in-
fected individuals eventually exhibited virologic progres-
sion (median time to detectable viremia of 3.8 years). In
one clinic-based cohort of more than 1300 individuals fol-
lowed for more than 10 years, only 8 (0.6%) were able to
maintain HIV RNA below 400 copies/ml, and in a second
related cohort, only 9 of 1551 (0.5%) met this definition
(Lambotte et al., 2005). Although none of these studies
provide a precise answer, they collectively suggest that
durable HIV control occurs in less than 1% of infected
individuals.
Epidemiologic factors associated with complete or near
complete HIV control in vivo have not been defined. Per-
sons destined to become HIV controllers appear to be
less likely to have symptomatic primary infection than
those destined to remain viremic (Madec et al., 2005a),
suggesting that the complex virus and host interactions
that lead to durable control of viral replication are already
at play during the earliest phases of HIV disease (Altfeld
et al., 2006). The route of HIV acquisition is not associated
with the likelihood of achieving an undetectable viral load
in the absence of therapy (Madec et al., 2005b) and is like-
wise not a strong predictor of immunologic nonprogres-
sion (Prins and Veugelers, 1997). Gender is also not a lim-
iting factor, with both male and female HIV controllers
defined, even though the average plasma HIV RNA ‘‘set
point’’ is lower in women than men, independent of all
other factors (Sterling et al., 1999). The potential impact
of race, geographic location, and/or viral subtype on
immunologic and virologic outcomes remains unknown,
although controllers have been identified in multiple
ethnicities and infected with different virus subtypes.
Potential Antiviral Mechanisms in HIV Controllers
The mechanisms of viral containment in HIV controllers
are largely unknown, despite the important implications
for current vaccine and therapeutic efforts. Studies thus
far have been limited to relatively small numbers of sub-
jects and have variably suggested either virus or host fac-
tors as potential explanations, but the precise mechanism
or combination of mechanisms accounting for durable
virologic control remains elusive.Immunity 27, September 2007 ª2007 Elsevier Inc. 407
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There is clear evidence that the pathogenicity of HIV iso-
lates can differ, as shown most conclusively in a group
of individuals all infected though blood transfusion from
a common donor, all of whom harbored a virus containing
a deletion in the nef gene and maintained low viremia for
years to decades (Deacon et al., 1995). However, many
of these persons have since progressed to AIDS (Churchill
et al., 2006), arguing that viral attenuation through the nef
gene does not necessarily lead to life-long control of HIV in
vivo. Several small studies and case reports have argued
that mutations or deletions within the HIV functional and
accessory genes (rev, tat, vif, vpr, and vpu) can lead to
virus control and/or immunologic nonprogression (Alex-
ander et al., 2000; Hassaine et al., 2000; Kirchhoff et al.,
1995; Lum et al., 2003; Wang et al., 1996; Yamada and
Iwamoto, 2000). Interpretation of most studies of viral at-
tenuation is difficult because they generally include small
numbers of patients, involve analysis of viral sequences
amplified from peripheral blood mononuclear cells rather
than the isolation of replication-competent HIV, often
lack a control group of individuals with uncontrolled HIV
replication, and almost invariably focused on individuals
who had low but detectable plasma HIV RNA.
It has proven difficult to isolate replication-competent
virus from HIV controllers. This may be due to exceedingly
low amounts of virus in such individuals or the presence of
attenuated virus. By using a highly sensitive coculture as-
say, Blankson and colleagues recently reported success-
ful isolation of replication-competent HIV from 4 of 10 con-
trollers. Virus from these individuals exhibited normal
replication kinetics in vitro and lacked any genetic inser-
tions of deletions, suggesting that host rather than virus
factors were responsible for durable control (Blankson
et al., 2007). The genetic diversity within the env gene of
plasma virus obtained from individuals in this same cohort
was exceedingly low, suggesting limited viral replication
and evolution during the entire course of the infection
(Bailey et al., 2006a). Collectively, these studies indicate
that near-complete host-mediated control of replication-
competent virus is possible; whether host or virus
factors contribute to control in those without detectable
replication-competent virus remains undefined.
Host Genetics
Themost consistent host factor associated with virus con-
trol is the presence of certain HLA class I alleles, particu-
larly HLA B alleles (Kiepiela et al., 2004). HLA-B5701 and
to a lesser extent HLA-B27 are strongly enriched among
North American and European cohorts of HIV controllers
compared to noncontrollers (Bailey et al., 2006b; Lam-
botte et al., 2005; Migueles et al., 2000). In addition, the
HLA B5703 allele (which is the prevalent B57 subtype in
Africans) is similarly highly enriched among African popu-
lations who are able to maintain low viral loads (Kiepiela
et al., 2007). These observations suggest a causal role
for the adaptive immune system because these HLA mol-
ecules are involved in immune recognition of virally in-
fected cells. The mechanistic role of HLA-5701 (and pre-
sumably other HLA alleles) in the control of HIV remains408 Immunity 27, September 2007 ª2007 Elsevier Inc.an open question, however, because (1) HLA-B5701 is in
strong linkage disequilibrium with the HCP5 gene, which
may be even more strongly associated with control, al-
though the mechanism for this association is not known
(Fellay et al., 2007), (2) HLA-5701-selected escape muta-
tions are not necessarily associated with viral rebound
(Bailey et al., 2006b), (3) many HLA-5701-positive individ-
uals with high viral loads lack clear evidence of T cell
escape mutations (Migueles et al., 2003), and (4) the
HLA-B5701 molecule interacts directly with certain killer
immunoglobulin-like receptors, suggesting agenetic com-
ponent mediated through the innate immune response
(Martin et al., 2007), as discussed below.
In addition to genetic factors influencing HIV-specific
immune responses, host genetic polymorphisms that af-
fect the ability of HIV to enter cells could have important
modulating effects on viral control. Homozygosity for
a 32 base pair deletion within the gene encoding CCR5,
a coreceptor for HIV entry into CD4-bearing cells, strongly
protects against acquisition ofHIV,whereas heterozygosity
for theCCR5D32 allele is associatedwith delayed progres-
sion to AIDS (Dean et al., 1996). There is also substantial
genetic variability within the CCR5 regulator sequences,
with some variants being associated with rapid disease
progression (Martin et al., 1998).
Although the expression of CCR5 has a clear and cen-
tral role in HIV pathogenesis, it is only part of a complex
story that also involves chemokine receptor ligand
expression. CCL3L1 is a gene that encodes MIP-1a, the
most suppressive host ligand for CCR5. The higher
the race-adjusted copy number of the CCL3L1 gene, the
lower the steady-state viral load (Gonzalez et al., 2005).
When both the CCR5 haplotype and the CCL3L1 copy
number are combined into genetic risk groups based on
risk of developing AIDS or death, the relative absence of
a detrimental CCR5 and CCL3L1 genotype within HIV
controllers becomes striking. Recent data indicate that
the mechanism by which these genetic characteristics
protect against disease progression is multifactorial and
involves restricted viral entry, preserved cell-mediated
immunity, and perhaps other mechanisms (Dolan et al.,
2007). Other chemokine receptors and/or chemokines re-
ceptor ligands (e.g., SDF-1) may also be causally associ-
ated with control (Winkler et al., 1998), although this has
not been formally tested among HIV controllers.
Innate Immunity
Acute HIV infection is associated with rapid and perhaps
irreversible destruction of the extensive CD4+ T cell popu-
lation that resides in gut-associated lymphoid tissue
(Mehandru et al., 2004). In animal models of AIDS virus in-
fection, half or more of the gut-resident CD4+ T cells are
lost in the first weeks of infection (Li et al., 2005; Mattapallil
et al., 2005). This loss of mucosal integrity results in im-
paired local cellular immunity (Brenchley et al., 2006)
and perhaps chronic translocation of microbial products,
which in turn contributes to persistent inflammation
(Brenchley et al., 2006). All of these potentially disease-
defining events occur before an adaptive T cell response
is generated, and therefore the earliest possible influence
Immunity 27, September 2007 ª2007 Elsevier Inc. 409
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nate immune response (Pichlmair and Reis e Sousa, 2007,
this issue of Immunity). Consistent with this hypothesis,
a recent series of host genetic studies found that individ-
uals who coexpress KIR3DS1 (a regulatory receptor on
the surface of NK cells) and HLA-Bw4-08I (a family of
HLA alleles that presumably binds to KIR3DS1 and acti-
vates NK cells) have lower viral load set points and re-
duced risk of progression to AIDS (Martin et al., 2002; Qi
et al., 2006). In a recent systematic study of HIV controllers
from our cohorts and others, there was a remarkable en-
richment of certain natural killer receptors. Strikingly, the
effect of HLA B57 on viral load was even greater when
expressed in the context of high levels of KIR3DL1, an in-
hibitory KIR, providing strong evidence that the innate
immune response plays a role in disease outcome. This
epistatic interaction between HLA B57 and KIR3DL1
may be at least in part explained by the fact that HLA
B57 is a Bw4 allele, which is the natural ligand for
KIR3DL1. Under normal conditions, the expression of
HLA B57 would keep NK cells from lysing these cells dur-
ing normal immunosurveillance. Were a cell to become
infected, this would lead to downregulation of HLA B57
and loss of the NK-inhibitory signal mediated through
KIR3DL1. Thus, the break would be released on these
NK cells, and lysis of the infected cells could ensue. This
mechanism provides a potential explanation as to why
persons expressing HLA B57 have less symptomatic
acute disease (Altfeld et al., 2003), because NK cells
may limit the initial viremia and might also lead to better
sparing of tissue-resident CD4+ T cells (Martin et al.,
2007). However, functional data on the potential contribu-
tion of innate immunity to initial viral control are needed.
Polymorphisms in toll-like receptor 9—which mediates in-
nate immune responses against DNA motifs common in
viruses and bacteria—have recently been shown to im-
pact the clinical course of disease, further suggesting
a link between the innate immune system and disease
pathogenesis (Bochud et al., 2007).
Another important component of the innate immune
system are the plasmacytoid dendritic cells (PDCs), which
produce type-I interferons (e.g., interferon-a), in response
to viral infections. HIV, which stimulates these cells via toll-
like receptors (Beignon et al., 2005), causes a rapid and
sustained decrease in the number of circulating PDCs
(Schmidt et al., 2006), presumably because HIV can di-
rectly infect these cells (Lore et al., 2005). PDCs are higher
in long-term clinical nonprogressors than progressors,
suggesting but not proving that these cells can protect
against disease progression, although it is possible that
their presence may simply be a consequence of low
amounts of viral replication (Soumelis et al., 2001).
CD8+ T Cell Immunity
Coincident with the decline in viremia after acute HIV
infection, there is an increase in HIV-specific CD8+ T cells
that are able to directly kill HIV-infected cells. These
observations, plus the consistent association between
certain HLA class I molecules and virus control, have
contributed to the widely held assumption that effectiveHIV-specific CD8+ T cell immunity is a dominant factor
driving the containment of HIV, but this remains controver-
sial and the mechanism has not been defined (Figure 2).
Although there is no clear association between the num-
ber of HIV-specific CD8+ T cells (as defined by inter-
feron-gamma production) and virologic control (Addo
et al., 2003; Betts et al., 2001), the function of these cells
is clearly higher in controllers compared to noncontrollers,
including the ability to proliferate upon encounter with HIV
antigens (Migueles et al., 2002), the ability to produce
the cytolytic protein perforin (Migueles et al., 2002), and
the ability to produce multiple cytokines (interferon-g,
MIP-1b, TNF-a, interleukin-2, and/or CD107a) (Betts et al.,
2006; Zimmerli et al., 2005). More recent studies show
that a virus ‘‘neutralization’’ assay can be used to assess
the antiviral potential of CD8+ T cells directly in a manner
comparable to that measured with antibody responses.
As compared to noncontrollers, freshly isolated CD8+ T
cells HIV controllers had higher capacities to inhibit HIV
Figure 2. Potential Factors Influencing HIV-Specific CTL and
Control of HIV Infection
Specific HLA class I alleles are associatedwith better disease outcome
in HIV infection, suggesting a link to HIV-specific, class I-restricted
CTL, but the mechanisms leading to better outcome remain unclear.
Possible factors linking class I alleles, CTL, and disease outcome in-
clude HLA-associated effects on the efficiency of antigen processing
and presentation; Nef-mediated downregulation of HLA alleles, be-
cause some expressed class I alleles interact with inhibitory receptors
on NK cells and thus would facilitate lysis by the innate arm of the im-
mune response; the avidity of the CTL-infected cell interaction through
the peptide-MHC-TCR complex; the TCR repertoire and ability to re-
spond to immune escape variants; the functional ability of cells to kill
infected targets; differences in specific soluble antiviral factors
released; and the effects of immunoregulatory networks on immune
control. Illustration by Andrew Tang.
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Cirion et al., 2007). Collectively, these data strongly argue
that potent CD8+ T cell responses directed at HIV are
causally related to the complete or near complete control
of HIV in at least some HIV controllers. Its should be em-
phasized, however, that many of these studies are by
necessity correlative in nature, making it difficult to rule
out the possibility that the preservations of potent HIV-
specific responses are a consequence rather than a cause
of HIV control.
Because of the complexities of studying the immune
response in humans, a number of groups have chosen
to use the SIV-infected macaque model as a means to
more carefully define the immunologic mechanisms for
virus control in vivo. Aswith humans, a small subset ofma-
caques is able to spontaneously control pathogenic SIV
infection. Thesemacaques are highly enriched for specific
class I alleles (Yant et al., 2006). Antibody depletion of
CD8+ T cells in these animals leads to rapid emergence
of SIV, arguing that control of the virus is at least partially
mediated via CD8+ T cells (and also arguing that these an-
imals were not infected with an attenuated virus) (Friedrich
et al., 2007). Of note, the reemergence of effective CD8+ T
cells was associated with the re-establishment of virus
control, although there was a shift in the immunodominant
epitopes.
The enhanced CD8+ T cell antiviral efficacy present in
HIV controllers may stem from the ability of certain HLA
molecules such as B57 to present a broad number of
HIV peptides for T cell recognition, the ability of thesemol-
ecules to generate high magnitude CD8+ T cell responses
(Altfeld et al., 2003; Jansen et al., 2005), and/or the ability
of these molecules to preferentially target highly con-
served proteins (Altfeld et al., 2003, 2006). With regard
to this latter concern, the amount of plasma viremia in
chronic infection is inversely associated with the breadth
the Gag-specific response and directly associated with
the breadth of Env-specific response (Kiepiela et al.,
2007). These opposite associations with viral control
may be explained by the relative impact of immune-
selected mutations on viral fitness. Mutations within Gag
may have a higher likelihood of inducing a fitness defect,
whereas mutations within the highly variable and pliable
Env protein may be less likely to result in substantial
growth impairment. This was well illustrated among a co-
hort of individuals with HLA B*5701, where it was shown
that mutations within a highly conserved p24 Gag peptide
epitope presented by this allele reduce replicative capac-
ity in vitro (Martinez-Picado et al., 2006) but do not nec-
essarily lead to virologic rebound in vivo (Bailey et al.,
2006b). When transmitted to non-HLA B57 individuals,
these escape mutations rapidly revert (Leslie et al.,
2004), providing strong evidence that these mutations re-
duce viral fitness in vivo. These observations suggest that
HIV is often constrained in its ability to escape selective
pressures that target highly conserved and functionally
important areas. Vaccine strategies that focus on highly
conserved and functionally important regions of the virus
could result in either an inability of the virus to escape or410 Immunity 27, September 2007 ª2007 Elsevier Inc.the emergence of an escape variant that replicates poorly
(Altfeld and Allen, 2006; Goulder and Watkins, 2004).
Alternatively, the enhanced antiviral effect observed for
Gag-specific CD8+ T cell responses may have to do with
earlier presentation of Gag epitopes on infected cells. Be-
cause preformed Gag protein is introduced into the cyto-
plasm during initial viral entry, it can immediately be pro-
cessed and presented to CTL. As a result, Gag-specific
CTL can recognize infected cells within 4 hr of infection,
whereas Env-specific responses are not active until
24 hr, because of the need for de novo protein synthesis
for the latter (Sacha et al., 2007).
In summary, these studies provide strong data suggest-
ing that HIV-specific CD8+ T cells may in some patients
lead to very efficient inhibition of viral replication. How-
ever, it is not clear whether such a response is sufficient
or even required. Many HIV controllers lack protective
HLA alleles and/or potent HIV-specific T cell responses,
while some noncontrollers have these characteristics.
Also, durable virus control is often observed even as the
virus develops mutations that confer resistance to HIV-
specific T cells (Bailey et al., 2006b). Hence, other host
and/or virus factors must be involved.
CD4+ T Cell Immunity
An obvious additional host factor modulating control
would be CD4+ ‘‘helper’’ T cells, which are required for
the long-term maintenance of antigen-specific CD8+
memory T cells (Grakoui et al., 2003; Lichterfeld et al.,
2004). HIV is essentially an infection of the immune sys-
tem, with the major target being CD4+ T cells. In acute
AIDS virus infections, there is a massive loss of CD4+ T
cells (Guadalupe et al., 2003; Li et al., 2005; Mattapallil
et al., 2005), and activated HIV-specific CD4+ T cells are
a primary ongoing target for infection (Douek et al.,
2002). Early virus-induced loss of those CD4+ T cells
that are critical in establishing effective adaptive immune
responses is widely believed to be one of the primary
reasons humans are not able to successfully control HIV
(Douek et al., 2002).
SIV infection of macaques leads to high viremia and
rapid disease progression in most but not all animals. As
outlined above, experimental depletion of CD8+ T cells
in macaques who control SIV replication leads to a rapid
rebound in SIV viremia (Friedrich et al., 2007). Interest-
ingly, the subsequent recovery of the immune system
was associated with emergence of robust SIV-specific
CD4+ and CD8+ T cell responses, which in turn was asso-
ciated with re-establishment of undetectable or low viral
loads (Friedrich et al., 2007), suggesting that both func-
tional antigen-specific CD4+ T cells are indeed required
in maintaining the capacity of CD8+ T cells to control viral
replication.
Data supporting a role for HIV-specific CD4+ T cells in
humans is obviously less direct and based primarily on
cross-sectional observations. In a cohort of 30 HIV con-
trollers in San Francisco (CA), the proportion of ‘‘polyfunc-
tional’’ HIV-specific CD4+ that express interferon-gamma
(IFN-g) and interleukin-2 (IL-2) was the single most consis-
tent correlate of control (Emu et al., 2005). Similar trends
Immunity 27, September 2007 ª2007 Elsevier Inc. 411
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a group of relative virologic controllers (HIV RNA < 1000
copies/mL) (Harari et al., 2004), in a cohort of nonprogres-
sors (defined based on CD4+ T cell counts) (Boaz et al.,
2002), and in elite controllers (Pereyra et al., 2007). Immu-
noregulatory networks related to CD4+ T cells may play
a role in the observed differences. The inhibitory immuno-
regulatory molecule CTLA-4 is upregulated on HIV-spe-
cific CD4+ T cells in all infected subjects except for the
HIV controllers, indicating a CD4+ T cell-specific marker
associated with viral containment (Kaufmann et al.,
2007). Expression of this receptor may diminish the ca-
pacity of CD4+ T cells to proliferate in response to HIV
peptides or p24 antigen, a function that is maintained in
long-term nonprogressors (most of whom had low viral
loads) (Martinez et al., 2005; Pontesilli et al., 1999; Rosen-
berg et al., 1997; Wilson et al., 2000). However, a substan-
tial proportion of HIV controllers—nearly 50%—have no
measurable HIV-specific CD4+ T cell activity as deter-
mined by cytokine production (Emu et al., 2006; Pitcher
et al., 1999). This again indicates that mechanisms other
than T cell immunity contribute to durable HIV control.
Humoral Immunity
Another major target for HIV vaccine development is neu-
tralizing antibodies. Most vaccinologists believe that the
only way to prevent HIV infection will be to develop a vac-
cine that can stimulate broadly crossreactive neutralizing
antibodies that will recognize circulating strains likely to
be encountered. Although older, more labor-intensive, as-
says suggested that antibodies able to neutralize virus are
present in vivo in some long-term nonprogressors (Cao
et al., 1995), new high-throughput assays that assess
the ability of patient-derived serum to neutralize autolo-
gous and heterologous viruses indicate that high-titer
neutralizing antibodies are rare in persons who maintain
low viral loads in the absence of therapy (Bailey et al.,
2006a; Deeks et al., 2006; Pereyra et al., 2007). Moreover,
env sequences in HIV controllers have small variable loops
and few predicted N-linked glycans, both of which sug-
gest limited pressure from neutralizing antibody in vivo
(Bailey et al., 2006a). Collectively, these studies strongly
argue against humoral immunity as a major mechanism
whereby rare individuals are able to achieve durable con-
trol of HIV replication in the absence of therapy.
Intracellular Immunity
In recent years, a number of intrinsic intracellular host fac-
tors that impair HIV replication have been identified, but
whether these play a role in limiting virus replication in
HIV controllers remains to be determined. One of these
is APOBEC3G, a cellular enzyme that potently restricts
HIV replication (Harris and Liddament, 2004). This cytidine
deaminase functions primarily by producing massive dG
/ dA hypermutation of the newly synthesized HIV DNA
formed during reverse transcription. HIV circumvents
this host defense system via the action of its accessory
protein Vif, which targets APOBEC3G for accelerated
degradation (Bishop et al., 2004; Sheehy et al., 2002).
Another mediator of innate cellular antiviral resistance is
Trim 5a, shown to modulate infection in a monkey modelof AIDS through a block before the initial step in reverse
transcription (Stremlau et al., 2004). Whether genetic var-
iability in these or other yet-to-be-defined host restriction
factors may modulate HIV control in humans is unclear.
Immune Activation and Disease Progression
HIV induces a strong and sustained inflammatory re-
sponse, with as many as 80% of CD8+ T cells in chronic
HIV infection expressing cell-surface markers associated
withTcell activation.Although theHIV-specificcomponent
of this inflammatory response may be beneficial, there is
an emerging consensus that much of the inflammatory
response is not directed at HIV and that this nonspecific
inflammatory response often does more harm than good.
Activated CD4+ T cells serve as the primary target of HIV
and thus may accelerate HIV disease progression simply
by enhancing the ability of the virus to replicate. Perhaps
more importantly, chronic nonspecific T cell activation
leads to accelerated turnover and death of CD4+ T cells,
which in turn may lead to the eventual exhaustion of the
immune system’s regenerative potential (Grossman et al.,
2002; Liu et al., 1998;McCune, 2001). The central indepen-
dent role of T cell activation in HIV disease pathogenesis is
illustratedby the fact that a small percentage (<10%) ofHIV
controllers exhibit progressive CD4+ T cell loss; this loss
occurs despite having no detectable viral replication by
standard assays and is associated with markedly elevated
CD8+ T cell activation (Hunt et al., 2007).
The degree of T cell activation is lower in controllers
than in noncontrollers, but higher than observed in HIV-
uninfected individuals and higher than observed in anti-
retroviral-treated patients (Emu et al., 2005; Hunt et al.,
2007). The mechanism for this abnormally elevated T cell
activation in HIV controllers is likely multifactorial and in-
cludes low amounts of HIV replication, chronic stimulation
and expansion of HIV-specific T cell responses, and/or the
presence of other coinfections (e.g., CMV). One recent
study postulated that HIV-mediated impairment of the
gastrointestinal mucosa results in chronic microbial trans-
location and activation of both the innate and adaptive
immune system. Lipopolysaccharide (endotoxin; LPS)
amounts—a presumed marker of gastrointestinal bacte-
rial translocation—are also higher in HIV controllers than
in HIV-negative individuals and correlate with T cell acti-
vation among HIV controllers (Hunt et al., 2007). These
observations were surprising because mucosal integrity
appears to be relatively intact, at least in the few control-
lers studied to date (Sankaran et al., 2005).
Compared to noncontrollers, HIV controllers havemuch
lower degrees of T cell activation while at the same time
have much higher numbers of HIV-specific T cells (Emu
et al., 2005). This balanced response in which the host re-
sponds appropriately to a prevalent antigen yet remains
relatively quiescent may prove to be the strongest func-
tional correlate of virologic control (Deeks and Walker,
2004). Consistent with this hypothesis, HIV-specific
CD8+ T cells from controllers express high amounts of
HLA-DR (a presumed activation marker) and are often
highly differentiated, even as the general CD8+ T cell
Immunity
Reviewpopulation lack evidence of high-level activation and/or
terminal differentiation (Addo et al., 2007; Emu et al.,
2005; Saez-Cirion et al., 2007). PD-1, a cell-surface mole-
cule that marks ‘‘exhausted’’ T cells, is generally upregula-
ted in both CD8+ (Day et al., 2006; Petrovas et al., 2006;
Trautmann et al., 2006) and CD4+ (Day et al., 2006) T cells
in HIV-infected persons but is greatly diminished among
HIV controllers (Kaufmann et al., 2007).
Given the deleterious effects of a sustained inflamma-
tory response, the human immune system goes to great
lengths to maintain immunologic harmony. Achieving
this outcomemay be the responsibility of T regulatory cells
(Treg cells), a subset of CD4+ T cells that suppress local T
cell activation via direct and indirect mechanisms (Thorn-
ton and Shevach, 2000). There are conflicting data regard-
ing the role of Treg cells in the immunopathogenesis of HIV
disease. Some have argued that these cells prevent or
suppress an effective immune response and are therefore
harmful whereas others have argued that these cells pre-
vent chronic immune activation and are therefore bene-
ficial. The only published work focusing on the role of
Treg cells in nonprogressors found that a relative absence
of these cells in the lymphoid tissue was associated with
durable virologic control (Nilsson et al., 2006), an effect
that was apparently mediated by the preservation of
potent HIV-specific T cell responses.
Defining theGenetic Basis for Control of a Chronic
Viral Infection: The International HIV Controller
Consortium
Although there are multiple factors that may play a role in
modulating the degree of HIV viremia, current data indi-
cate that durable in vivo control of HIV cannot be entirely
explained by virus or host factors studied to date. Be-
cause of the advances of the Human Genome Project, it
is now possible to search for novel host genetic factors
that influence disease by high-throughput sequencing of
single-nucleotide polymorphisms that have been defined
within the 3 billion nucleotide human genome (Christensen
and Murray, 2007). These types of whole-genome associ-
ation scans (WGAS) have successfully identified genetic
variants that have important roles in common diseases
and clinically relevant traits, in some cases with as few
as 100 subjects (Plenge and Rioux, 2006). Recently, a
whole-genome association scan in persons with different
viral load set points after acute HIV infection was reported,
revealing two genetic polymorphisms that together ac-
count for 15%of the variability in viral load set point (Fellay
et al., 2007). Because this type of genetic screen is not bi-
ased toward any gene or pathway of known biologic func-
tion, this approach has the greatest opportunity to identify
factors previously unidentified as important in viral control.
To this end, a new international consortium has been es-
tablished with the plan to recruit 1,000 HIV controllers
and perform a WGAS by sequencing 650,000 single-
nucleotide polymorphisms within the human genome. The
International HIV Controller Consortium consists of scien-
tists, health-care providers, AIDS services organizations,
and patients, with the objective of rapidly recruiting412 Immunity 27, September 2007 ª2007 Elsevier Inc.persons who fit the HIV-controller definition. To date
more than 300 elite controllers have been identified, con-
sent obtained, DNA extracted, and genomic sequencing
commenced. These large numbers will allow for haplo-
typic studies examining the contribution of multiple
Table 1. Potential Mechanisms for Virus Control in HIV
‘‘Controllers’’
Mechanism Evidence
Adaptive Immune Response
HIV-specific CD8+ T cells Controllers are enriched in
certain class I HLA alleles
and often haveCD8+ T cells
that produce multiple
cytokines and/or
proliferate in response to
HIV peptides
HIV-specific CD4+ T cells Controllers often have
CD4+ T cells that express
high amounts of HIV-
specific IL-2 and
interferon-g in response to
HIV peptides
Innate Immune Responses
Natural killer cells Controllers are strongly
enriched for certain NK cell
receptors that are involved
in regulating the function
of these cells
Plasmacytoid dendritic
cells (PDCs)
The number and/or
function of PDCs are high
in some controllers
Reduced cellular entry Controllers are enriched
for genetic polymorphisms
in the CCR5 pathway
associated with reduced
amounts of this viral
coreceptor and/or have
high amounts of CCR5
ligands that may compete
with HIV for cell entry
Immunoregulation
T regulatory cells T regulatory cells—which
blunt antigen-specific T cell
responses—are low in
some HIV controllers,
particularly in lymphoid
tissues
Attenuated viruses Some controllers
harbor viruses containing
mutations and/or deletions
in key regulatory
or accessory genes,
particularly nef
Mutations induced
by CD8+ T cell pressure
leading to reduced viral
fitness
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Reviewfactors mentioned above that appear to contribute to du-
rable and perhaps indefinite control of HIV replication.
Conclusions
Long-term containment of an otherwise chronic progres-
sive infection provides hope for successful control of
HIV and other chronic viral infections such as HCV. Be-
cause most vaccines protect against disease rather than
against infection, it is critical to understand the mecha-
nisms of natural viral control in those rare cases in which
this occurs. Indeed, HIV controllers who maintain viral
loads below the limits of detection exhibit a degree of con-
trol that would lead to contraction of the global epidemic,
because of both decreased progression and decreased
risk of transmission. Data thus far generated from small
studies indicate a high association between virus control
and the presence of certain host HLA class I alleles and
CD8+ T cell responses generated through these alleles,
as well as strong virus-specific CD4+ T cell responses.
The collective data outlined here, however, illustrate that
no single factor thus far defined is completely protective;
nor, for that matter, is any one factor strictly required
(Table 1). Just as large, well-designed studies have been
needed to carefully define which combinations of drugs
work best for the therapeutic management of HIV infection
(Hammer et al., 2006), we believe that large, well-designed
studies are needed to define which combinations of host
factors are most likely to result in such remarkable virus
control. Efforts are now underway to develop the large
cohorts necessary to initiate such work.
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